452 405

Cited 92 times in

Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model

DC Field Value Language
dc.contributor.author김주항-
dc.contributor.author김호근-
dc.contributor.author윤채옥-
dc.date.accessioned2015-06-10T12:04:48Z-
dc.date.available2015-06-10T12:04:48Z-
dc.date.issued2006-
dc.identifier.issn1078-0432-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/109153-
dc.description.abstractPURPOSE: We investigated whether an armed viral platform, where lytic property of a viral infection is coupled to viral-mediated delivery of therapeutic genes, could increase the therapeutic potential of a viral-based therapy. EXPERIMENTAL DESIGN: We generated interleukin (IL)-12-expressing oncolytic adenovirus (YKL-IL-12) and IL-12- and B7-1-expressing (YKL-IL12/B7) oncolytic adenovirus. Therapeutic efficacy of these newly engineered adenoviruses was then evaluated in vivo using an immunocompetent mouse bearing murine melanoma B16-F10 tumors. Overall survival was assessed with the Kaplan-Meier method. The induction of immune cell cytotoxicity was assessed by CTL assay, IFN-gamma enzyme-linked immunospot assay, and immunohistochemical studies. RESULTS: YKL-IL12/B7 oncolytic adenovirus, expressing both IL-12 and B7-1, showed a higher incidence of complete tumor regression compared with the analogous oncolytic adenovirus, YKL-1, or IL-12-expressing, YKL-IL12. Significant survival advantage was also seen in response to YKL-IL12/B7. Moreover, IL-12 and IFN-gamma levels produced in tumors treated with YKL-IL12/B7 was significantly greater than those treated with YKL-IL12. The enhanced survival advantage was mediated by the induction of immune cell cytotoxicity. In agreement with these results, massive infiltration of CD4(+) and CD8(+) T cells into tissues surrounding the necrotic area of the tumor was observed following in situ delivery of YKL-IL12/B7. CONCLUSION: Combination of oncolysis and the enhancement of antitumor immune response by oncolytic adenovirus expressing both IL-12 and B7-1 elicits potent antitumor effect and survival advantage.-
dc.description.statementOfResponsibilityopen-
dc.format.extent5859~5868-
dc.relation.isPartOfCLINICAL CANCER RESEARCH-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenoviridae/genetics*-
dc.subject.MESHAnimals-
dc.subject.MESHB7-1 Antigen/genetics-
dc.subject.MESHB7-1 Antigen/immunology-
dc.subject.MESHB7-1 Antigen/metabolism*-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHGene Expression-
dc.subject.MESHGenetic Therapy/methods*-
dc.subject.MESHGenetic Vectors/administration & dosage-
dc.subject.MESHHumans-
dc.subject.MESHInterferon-gamma/metabolism-
dc.subject.MESHInterleukin-12/genetics-
dc.subject.MESHInterleukin-12/immunology-
dc.subject.MESHInterleukin-12/metabolism*-
dc.subject.MESHMale-
dc.subject.MESHMelanoma, Experimental/immunology-
dc.subject.MESHMelanoma, Experimental/therapy*-
dc.subject.MESHMice-
dc.subject.MESHMice, Inbred C57BL-
dc.subject.MESHMice, Nude-
dc.subject.MESHNeoplasms/immunology-
dc.subject.MESHNeoplasms/therapy*-
dc.subject.MESHOncolytic Virotherapy/methods*-
dc.subject.MESHT-Lymphocytes/immunology-
dc.subject.MESHTumor Cells, Cultured-
dc.subject.MESHVirus Replication/drug effects-
dc.titleEnhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pathology (병리학)-
dc.contributor.googleauthorYoung-Sook Lee-
dc.contributor.googleauthorJoo-Hang Kim-
dc.contributor.googleauthorKyung-Ju Choi-
dc.contributor.googleauthorIl-Kyu Choi-
dc.contributor.googleauthorHoguen Kim-
dc.contributor.googleauthorSungae Cho-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorChae-Ok Yun-
dc.identifier.doi10.1158/1078-0432.CCR-06-0935-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00945-
dc.contributor.localIdA01183-
dc.contributor.localIdA02614-
dc.relation.journalcodeJ00564-
dc.identifier.pmid17020994-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameKim, Ho Keun-
dc.contributor.alternativeNameYun, Chae Ok-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorKim, Ho Keun-
dc.contributor.affiliatedAuthorYun, Chae Ok-
dc.rights.accessRightsfree-
dc.citation.volume12-
dc.citation.number19-
dc.citation.startPage5859-
dc.citation.endPage5868-
dc.identifier.bibliographicCitationCLINICAL CANCER RESEARCH, Vol.12(19) : 5859-5868, 2006-
dc.identifier.rimsid50625-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Research Institute (부설연구소) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.